Literature DB >> 991073

Erythroplasia of Queyrat: treatment with topical 5-fluorouracil.

D K Goette, T E Carson.   

Abstract

Seven adult men with biopsy-confirmed erythroplasia of Queyrat (EQ) were cured of their disease with topically applied 5-fluorouracil (5-FU) under occlusion. Post-treatment biopsy specimens revealed normal histologic findings and recurrence-free follow-up periods extended up to 70 months. It is suggested that topical 5-FU is the treatment of choice for histologically confirmed EQ because of its superior results compared with thoseof surgery or radiation therapy. Our view is corroborated by several single case reports of EQ similarly treated.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 991073     DOI： 10.1002/1097-0142(197610)38:4<1498::aid-cncr2820380409>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  8 in total

1.  Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

Review 2.  Erythroplasia of Queyrat treated by laser and light modalities: a systematic review.

Authors:  Eric L Maranda; Austin H Nguyen; Victoria M Lim; Vidhi V Shah; Joaquin J Jimenez
Journal:  Lasers Med Sci       Date:  2016-06-21       Impact factor: 3.161

Review 3.  Challenges and controversies in the management of penile cancer.

Authors:  Majid Shabbir; Oliver Kayes; Suks Minhas
Journal:  Nat Rev Urol       Date:  2014-11-18       Impact factor: 14.432

4.  Practice parameters for the diagnosis and treatment of anal intraepithelial neoplasia (AIN) on behalf of the Italian Society of Colorectal Surgery (SICCR).

Authors:  G A Binda; G Gagliardi; I Dal Conte; M Verra; P Cassoni; E Cavazzoni; E Stocco; S Delmonte; P De Nardi; L Sticchi; M Mistrangelo
Journal:  Tech Coloproctol       Date:  2019-06-26       Impact factor: 3.781

Review 5.  Treatment of cancer of the penis--a review.

Authors:  V Srinivas; S A Khan
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

Review 6.  Primary penile cancer organ sparing treatment.

Authors:  Roman Sosnowski; Marcin Kuligowski; Olga Kuczkiewicz; Katarzyna Moskal; Jan Karol Wolski; Marc A Bjurlin; James S Wysock; Piotr Pęczkowski; Chris Protzel; Tomasz Demkow
Journal:  Cent European J Urol       Date:  2016-10-17

Review 7.  Topical Therapy for non-invasive penile cancer (Tis)-updated results and toxicity.

Authors:  Aditya Manjunath; Thomas Brenton; Sarah Wylie; Catherine M Corbishley; Nick A Watkin
Journal:  Transl Androl Urol       Date:  2017-10

Review 8.  Penile-sparing modalities in the management of low-stage penile cancer.

Authors:  Paurush Babbar; Nitin Yerram; Alice Crane; Daniel Sun; Kyle Ericson; Andrew Sun; Abhinav Khanna; Hadley Wood; Andrew Stephenson; Kenneth Angermeier
Journal:  Urol Ann       Date:  2018 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.